Technical / White Paper

Assessing Pre-Existing Antibodies in Biotheraputic Development

Format: PDF file | Document type: Technical / White Paper

Assessing Pre-Existing Antibodies in Biotheraputic Development

Related categories: Analytical testing, QC, Bulk ingredients, Contract sales & marketing, Data management, Drug delivery, formulation, Fill & finish, packaging, Phase I-II, Phase III-IV, Preclinical, Regulatory affairs, Supply chain, logistics, Validation services, Contract Manufacturing, Medical Devices

Immunogenicity is the leading reason that biologics fail in clinical trials, and thus it has become imperative for drug development programs to include an immunogenicity risk assessment, leading to a clinical strategy. Detecting and characterizing the formation of treatment emergent anti-drug antibodies (ADAs) is critical in understanding patient safety, pharmacokinetics (PK), and pharmacodynamics (PD). An early strategy to minimize immune responses against the therapeutic may both improve clinical outcomes and reduce time to market.

Related resources from Frontage Laboratories

Supplier info centre